OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
March 08, 2023
Webinar Date/Time: Thu, Mar 30, 2023 11:00 AM EDT
Webinar Date/Time: Thu, Apr 6, 2023 11:00 AM EDT
March 07, 2023
In this episode, Rhonda Henry and Adam Mendizabal from Emmes discuss the role CROs play in cell and gene therapies undergoing clinical trials at all stages.
March 03, 2023
This article discusses the evaluation of paired content uniformity and weight variation data sets using F and T tests to ensure that batches meet compendial requirements.
Lipids aren’t the only important ingredients influencing stability and in vivo performance.
Advancements in therapeutic modalities are necessitating change in drug delivery to help negate some of the expense of development and manufacturing.
March 01, 2023
Webinar Date/Time: Friday, March 24, 2023 at 11am EST | 10am CST | 8am PST
Key challenges posed to autologous and allogeneic treatments could be resolved by in-vivo CAR-T gene therapies.
February 21, 2023
In this episode, Ana Ladino provides an update on the acceptance of a novel excipient onto CDER’s pilot program.
February 15, 2023
Webinar Date/Time: Wed, Mar 1, 2023 11:00 AM EST